Showing results (41-50 of 75) with videos related to
Sort By:
Pageof 8
Molecular Biotechnology|September 23, 2023
Circ_103809 Aggravates the Malignant Phenotype of Pancreatic Cancer Through Modulating miR-197-3p/TSPAN3 AxisXiang Wu, Shuping Zhou, Luoluo Wang, et al.Artificial Cells, Nanomedicine, and Biotechnology|October 27, 2017
Trastuzumab-modified DM1-loaded nanoparticles for HER2<sup>+</sup> breast cancer treatment: an in vitro and in vivo studyLing Rong, Shuping Zhou, Xinkuang Liu, et al.Journal of Gastroenterology and Hepatology|June 25, 2026
Coal Dust-Mimetic Carbon Nanoparticles Induce Colonic Epithelial Cell Senescence via p16/p21 Dual Pathways and Promote Colonic Inflammatory ResponseYang Wang, Chuanzhu Zhang, Xiaoyan Li, et al.Cancer Medicine|June 18, 2025
MicroRNA Let-7b-5p Targets IGF1R to Inhibit the Progression of Hepatocellular Carcinoma Through the AKT/mTOR PathwayJiaojiao Liang, Amin Li, Jun Chen, et al.Medicine|October 3, 2019
Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in ChinaRongxin Yao, Xudong Hu, Shuping Zhou, et al.Science Progress|April 27, 2022
Th1 immune maturation effects of <b></b>Meixiang Zhou, Shuping Zhou, Kun Han, et al.Expert Opinion on Drug Delivery|February 15, 2020
Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticlesBinquan Wu, Amin Li, Yinci Zhang, et al.Journal of Innate Immunity|October 4, 2014
Interferon-γ inhibits nonopsonized phagocytosis of macrophages via an mTORC1-c/EBPβ pathwayZengfu Wang, Shuping Zhou, Chenming Sun, et al.Plant Physiology and Biochemistry : PPB|February 8, 2025
Light regulates SlCOP1-mediated degradation of SlJAF13, a transcription factor essential for anthocyanin biosynthesis in Aft tomato fruitZiqian Cao, Yunzhu Chen, Yuansen Chen, et al.Molecular Medicine Reports|May 13, 2021
LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathwayRuyue Xu, Yinci Zhang, Amin Li, et al.Pageof 8